Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Pronostics to supply Hannover Medical School with next generation diagnostics for autoimmune disease


Cambridge, UK, 10 September 2008 … Pronostics Ltd, developer and manufacturer of next generation multiplexed diagnostics for healthcare providers and the pharmaceutical industry, has signed a deal with Hannover Medical School to provide its proprietary platform for the diagnosis of autoimmune disease.

The deal, which is through Pronostics German distributor, Medipan, will see Hannover Medical School, one of the worlds leading medical centres, use the UltraPlex™ hardware and ANA kits for the diagnosis of autoimmune disease.

The UltraPlex™ solution eliminates the possibility of subjective errors, removes non-specific positive results and focuses on clinically significant results, with known disease association. Its introduction will also significantly reduce test turn-a-round times and laboratory costs.

Dr Torsten Witte, from Hannover Medical School, said: “The UltraPlex™ system and ANA assay is a powerful tool in the rapid and accurate diagnosis of auto-immune diseases. This combined with its ease of use, makes it an excellent system for busy pathology laboratories, ensuring patients can be quickly diagnosed and the relevant treatments prescribed.”

Robert Booth, CEO of Pronostics added: “Hannover Medical School is one of the world’s leading medical centres, and we are extremely pleased that an organisation with its global reputation has decided to use our UltraPlex™ technology after extensive evaluation.”

Dr. Dirk Roggenbuck, Managing Director of Medipan added: “We are extremely pleased to have been able to secure our first deal in the German market for Pronostics with Hannover Medical School, a world leading medical centre which has recognized the value of Pronostics UltraPlex™ solution.”

The UltraPlex™ ANA assay, consists of 11 tests in one, providing valuable time and cost savings compared to serial testing approaches or current multiplexing methods. It allows hospitals and laboratories to perform fully automated tests on patient samples and gives both quantitative and qualitative results for antibodies in autoimmune diseases.

-ends-

Notes to editors

About PRONOSTICS

Pronostics is a leading clinical diagnostics company, providing diagnostic and disease monitoring applications, through its core UltraPlex™ technology. UltraPlex™ is a ‘next generation’ multiplexing solution enabling tens to hundreds of assays to be performed simultaneously in a single test using a microscopic digital bar-coding system. UltraPlex™ improves the speed, efficiency and cost of clinical diagnostic testing and drug development and combined with Pronostics’ FingerPrint Immunomics technology, is enabling the next generation multivariate diagnostics.

Websites: http://www.pro-nostics.com and http:///www.ultraplex.com


For further information, please contact:

College Hill:

Tony Stephenson, Cosima Zerdik, Katja Stout
Phone: +44 20 7457 2020
Email: pronostics@collegehill.com


Publisher Contact Information:

College Hill
+44 20 7457 2020
pronostics@collegehill.com

Company profile of SmartBead Technologies (Merged w FingerPrint Diagnostics to form Pronostics Ltd.
Past press releases of SmartBead Technologies (Merged w FingerPrint Diagnostics to form Pronostics Ltd..

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.